Self-Assembling Raloxifene Loaded Mixed Micelles: Formulation Optimization, In Vitro Cytotoxicity and In Vivo Pharmacokinetics
- 103 Downloads
Raloxifene (RLX) has been strongly recommended for postmenopausal women at high risk of invasive breast cancer and for prevention of osteoporosis. However, low aqueous solubility and reduced bioavailability hinder its clinical application. The objective of this study was to explore the potential of RLX loaded mixed micelles (RLX-MM) using Pluronic F68 and Gelucire 44/14 for enhanced bioavailability and improved anticancer activity on human breast cancer cell line (MCF-7). RLX-MM were prepared by solvent evaporation method and optimized using 32 factorial design. The average size, entrapment efficiency and zeta potential of the optimized formulation were found to be 190 ± 3.3 nm, 79 ± 1.3%, 13 ± 0.8 mV, respectively. In vitro study demonstrated 74.68% drug release from RLX-MM in comparison to 42.49% drug release from RLX dispersion. According to the in vitro cytotoxicity assay, GI50 values on MCF-7 breast cancer cell line for RLX-MM and free RLX were found to be 22.5 and 94.71 μg/mL, respectively. Significant improvement (P < 0.05) in the anticancer activity on MCF-7 cell line was observed in RLX-MM over RLX pure drug. Additionally, oral bioavailability of RLX-MM was improved by 1.5-fold over free RLX when administered in female Wistar rats. Incorporation of RLX in the hydrophobic core and improved solubility of the drug due to hydrophilic shell attributed to the enhanced cytotoxicity and bioavailability of RLX-MM. This research establishes the potential of RLX loaded mixed micelles of Pluronic F68 and Gelucire 44/14 for improved bioavailability and anticancer activity on MCF-7 cell line.
Key Wordsraloxifene mixed micelles Pluronic F68 Gelucire 44/14 factorial design anticancer activity
The authors thank Zim Laboratories (Nagpur, India) and Novartis Pharmaceuticals (Hyderabad, India) for providing us gift samples of raloxifene and carbamazepine, respectively. The authors are much obliged to Alembic Pharmaceuticals (Mumbai, India) and Gattefossé S.A.S. (Saint Priest, France) for providing Pluronic F68 and GL44 gift samples, respectively. Radhika Kanade would also like to thank AICTE (New Delhi, India) for providing financial support during the entire research study.
- 5.Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of Raloxifene. J Natl Cancer Inst. 2004;96(23):1751–61. https://doi.org/10.1093/jnci/djh319.CrossRefPubMedGoogle Scholar
- 6.Mizuma T. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm. 2009;378(1–2):140–1. https://doi.org/10.1016/j.ijpharm.2009.05.044.CrossRefPubMedGoogle Scholar
- 8.Thakkar H, Nangesh J, Parmar M, Patel D. Formulation and characterisation of lipid based drug delivery systems of raloxifene—microemulsions and self-microemulsifying drug delivery system. J Pharm Bioallied Sci. 2011;3(3):442–8. https://doi.org/10.4103/0975-7406.84463.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.BASF, The Chemical Company. http://worldaccount.basf.com/wa/NAFTA/Catalog/ChemicalsNAFTA/doc4/BASF/PRD/30089194/.pdf?asset_type=pi/pdf&language=EN&urn=urn:documentum:eCommerce_sol_EU:09007bb28001f73c.pdf. Accessed - 26 Nov 2015.
- 23.Patel HR, Patel RP, Patel MM. Poloxamers: a pharmaceutical excipients with therapeutic behaviours. Int J PharmTech Res. 2009;1(2):299–303.Google Scholar
- 24.Patel P, Mehta T, Panchal S. Preparation, evaluation and comparison of lipid based drug delivery systems of tacrolimus. Int J Pharm Pharm Sci. 2014;6(2):588–91.Google Scholar
- 25.Upadhyay P, Kumar J, Kumar A. Gelucire: an alternative formulation technological tool for both sustained and fast release of drug in treating disbetes milletus type-II disease. J Sci Ind Res. 2013;72:776–80.Google Scholar
- 30.Fisher R. Introduction to “The arrangement of field experiments”. J Minist Agric G B. 1926;33:503–13.Google Scholar
- 31.Kuchekar A, Pawar A. Screening of factors using plackett burman design in the preparation of capecitabine loaded nano polymeric micelles. Int J Pharm Pharm Sci. 2014;6(5):489–96.Google Scholar
- 32.Suneetha D, Lakshmana Rao A. A new validated RP-HPLC method for the estimation of RLX in pure and tablet dosage form. Rasayan J Chem. 2010;3(1):117–21.Google Scholar
- 33.Mourya VK, Nazma I, Nawale RB, Kulthe SS. Polymeric micelles: general considerations and their applications. Ind J Pharm Edu Res. 2011;45(2):128–38.Google Scholar
- 34.Li J, Jiang Y, Wen J, Fan G, Wu Y, Zhang C. A rapid and simple HPLC method for the determination of curcumin in rat plasma: assay development, validation and application to pharmacokinetic study of curcumin liposome. Biomed Chromatogr. 2009;23(11):1201–7. https://doi.org/10.1002/bmc.1244.CrossRefPubMedGoogle Scholar
- 40.Jha RK, Tiwari S, Mishra B. Bioadhesive microspheres for bioavailability enhancement of RLX hydrochloride: formulation and pharmacokinetic evaluation. Am Assoc Pharm Sci. 2011;12(2):650–7.Google Scholar